A comparative analysis of the phase 2 BiCAR trial found that accelerated glofitamab reduced mortality risk after anti-CD19 CAR T-cell therapy failure in diffuse large B-cell lymphoma. The report frames glofitamab as a bispecific option for patients who do not benefit from or relapse following CAR T. The BiCAR readout matters for treatment sequencing, where many patients require a next-line strategy despite limited guidance post–CAR T failure. If validated in broader datasets, accelerated administration could become a differentiator in operationalizing bispecifics. The result also reinforces how quickly the field is iterating on salvage strategies after cell therapy setbacks.
Get the Daily Brief